Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis Patients

0

Posted by Cystic Fibrosis News From Medical News Today | Posted in Respiratory / Asthma | Posted on 25-02-2010

Country Concert for Cystic Fibrosis

Aradigm Corporation (OTCBB:ARDM) (the "Company") announced that it dosed the first patient in the U.S...


Write a comment

You must be logged in to post a comment.